Takara Bio Inc.

Quick facts

Phase 3 pipeline

• TBI-1301 · Oncology
  TBI-1301 is a monoclonal antibody targeting CD47.

Phase 2 pipeline

• HF10 plus Ipilimumab · Oncology
  HF10 plus Ipilimumab is a combination of a heat shock protein 90 (HSP90) inhibitor and a CTLA-4 inhibitor, which works by blocking the activity of heat shock protein 90 and cytotoxic T-lymphocyte-associated protein 4, respectively, to enhance the immune response against cancer cells.

Phase 1 pipeline

• TBI-1501

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Takara Bio Inc. portfolio CI brief
• Takara Bio Inc. pipeline updates RSS